Quick Dispatch:
Your surpass trial tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass trial tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial ships.
Need Help?
Questions about surpass trial tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass trial tirzepatide Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
28.40
Effects of tirzepatide on adjudicated cardiovascular events in
20.87
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
28.88
Does Tirzepatide Cause Indigestion? Side Effects Explained
20.86
Dealing With Mounjaro Side Effects
29.11
Does Tirzepatide Cause Acid Reflux? FDA Data and Management
26.61
Tirzepatide Side Effects: Common & Rare Reactions Explained
26.93
